Space Pharm Showcases AI-Powered Peptide Drug Platform at Hong Kong-Swiss Biotech Roundtable, Advances Cross-Border Innovation and IPO Preparations
On May 20, 2026, the Health Bureau of the Hong Kong Special Administrative Region held in Zurich, SwitzerlandHong Kong‑-Swiss Biotech Roundtable, focusing on the development of Hong Kong as an international hub for medical innovation, reforms in new drug approval, collaboration in clinical trials, and the translation of biomedical research outcomes.Dr. He Runze, Founder and CEO of Space Pharmaceuticals AG / Shanghai Shengpu Zetai Pharmaceutical Technology Co., Ltd.Invited to attend the conference and share with the delegation of the HKSAR Government, representatives of the Swiss Biotech Association, and multinational pharmaceutical companies on how the company leveragesChemical Space Theory + AI-Driven, Globally Leading Peptide Drug Discovery Platform, jointly promoting cross-border cooperation in pharmaceutical innovation between China and Switzerland.
This conference is organized byProfessor Lo Chung-mau, Secretary for Health of the Hong Kong Special Administrative RegionLed the delegation in attendance, with a focus on introducing innovative frameworks such as Hong Kong’s “First-Tier Approval” mechanism for new drugs, the Greater Bay Area International Clinical Trial Center, and the Hong Kong Centre for Drug and Medical Device Regulation. The delegation encouraged Swiss innovative pharmaceutical companies to leverage Hong Kong’s advantages to enter the Greater Bay Area and the Chinese market, thereby facilitating the efficient translation of cutting-edge biotechnologies.
(Group Photo of Attendees)
01
Innovation Rooted in the Source of Chemical Space
Building Full-Stack AI Capabilities for Peptide Drug Development
Space Pharm byProfessor Jean‑Louis Reymond, University of Bern, Switzerland, founder of chemical space theoryCo-founded with its headquarters in Bern, Switzerland, the company has established R&D, clinical, production, and commercialization centers in Hong Kong, Shanghai, Xiamen, and other locations. Its global R&D team comprises over 60 members, including more than 10 full-time PhD holders based in Switzerland and over 50 R&D personnel in China.
The company, withNavigate Chemical Spaceas the core, building a globally uniqueGDB Database + AI Algorithms + Innovative Peptide Drug DevelopmentIntegrated System:
● Supported by the world’s largest virtual molecular library:Equipped with the GDB‑17 (166.4 billion compounds), GDB‑20 (3.2 trillion compounds), and GDB‑PepSpace™️ chemical space databases, it covers an ultra-large-scale chemical universe on the order of 10^60, providing an unparalleled data foundation for de novo molecule discovery.
● Full-Stack AI Drug Discovery Technology Matrix: Four core algorithms—PDGA, a proprietary genetic algorithm for peptide design; PPB3, a multi-target prediction model; T-MAP, high-dimensional chemical space visualization; and DDN Agent, an all-in-one intelligent agent for drug design—enable end-to-end AI acceleration from target discovery and molecule generation to hit screening, lead optimization, and PCC validation. Target analysis is completed in 1–2 days, molecular design in 2–5 days, and progression to the PCC stage can be achieved in as little as 4–12 months.
● Technical Barriers in Peptide and Cyclic Peptide Technologies: Focused on oral peptides, cyclic peptides, peptide-drug conjugates (PDCs), and peptide-siRNA delivery systems, it possesses customized building blocks such as non-natural amino acids, cyclization, and conformational locking to overcome challenges in peptide druggability, stability, and oral absorption, covering major indications including metabolic diseases, autoimmune disorders, ophthalmology, and central nervous system conditions.
(Space Pharmaceuticals AG Decodes the 1,060-Peptide Universe with AI)
02
From AI Design to Clinical Translation
Building a Globalized R&D and Production Closed Loop
Driven by the dual engines of Swiss-originated innovation and efficient implementation in China, Space Pharm has establishedAI Design — Laboratory Validation — Preclinical Development — GMP ManufacturingComplete Closed Loop:
● Swiss AI Innovation Center: Jointly established a laboratory with the University of Bern, focusing on chemical space computation, AI model training, and algorithm iteration, continuously expanding the GDB database while maintaining global leadership.
● Comprehensive Industrial Support Across the Entire Supply Chain in China: Shanghai serves as the center for new drug business in China, coordinating BD, clinical development, and commercialization; Xiamen is positioned for preclinical research and formulation development; Zhangzhou is building a molecular library synthesis platform.
● Diversified Pipeline Matrix: Multiple oral cyclic peptide and siRNA delivery projects, covering immunology and central nervous system therapeutics, and extending into non-pharmaceutical fields such as anti-aging medical aesthetic peptides and green peptide-based pesticides.
(Space Pharmaceuticals AG has built full-stack capabilities for AI-driven peptide drug development)
03
Deepening Collaboration with Global Innovative Pharmaceutical Companies
Anchoring Hong Kong: A New Blueprint for Translation and Capitalization
Dr. He Runze stated in his remarks at the roundtable discussion that Hong Kong serves as a key hub connecting Switzerland’s source innovation with China’s vast market, inNew Drug Approval, Clinical Trials, Intellectual Property, International Capital Matchmakingpossesses unique advantages in areas such as.
● Deepen strategic cooperation with global innovative pharmaceutical companies: Leveraging the GDB chemical space and AI-powered peptide platform, we engage in business development collaborations with leading global pharmaceutical companies in areas such as innovative targets, novel molecule discovery, and preclinical development, accelerating the realization of first-in-class (FIC) and best-in-class (BIC) drug pipelines.
● Leveraging China's Engineer Dividend: Leverage China’s strong talent advantages in experimental R&D, process development, and clinical operations to significantly enhance R&D efficiency, reduce costs, and support rapid iteration and scaled delivery of global projects.
● Deepening R&D and Capitalization in Hong Kong:Establish an AI Joint Laboratory for Personalized Peptide Therapeutics in Hong Kong, leveraging academic resources from the Hong Kong University of Science and Technology and the University of Bern in Switzerland to develop AI-driven personalized treatment engines for metabolism, autoimmune diseases, oncology, and anti-aging; simultaneously advance preparations for listing under Chapter 18C of the Hong Kong Stock Exchange, facilitate access to international capital channels, and support the efficient commercialization and global expansion of innovative achievements.
In the future, the company will continue to decode the 10^60-peptide universe with AI, collaborate with global partners to build a world-leading AI-driven peptide innovative drug platform, and deliver more efficient and accessible breakthrough therapies to patients.
Professor Lo Chung-mau, Secretary for Health of the Hong Kong Special Administrative Region (right), and Dr. Ho Yun-chak of Space Pharmaceuticals AG (left)
About Space Pharm
Space Pharm is a globally leading AI-driven pharmaceutical company centered on the discovery and co-development of peptide therapeutics. The company possesses the world’s largest peptide database and deeply integrates cutting-edge computational chemistry and AI technologies from Switzerland with large-scale synthesis and manufacturing capabilities in China. Its business chain spans the entire spectrum from peptide target identification and AI-based design to preclinical development and commercial-scale production. We are committed to leveraging artificial intelligence to design novel peptide molecules, accelerating the speed and efficiency of new drug development, and becoming the most trusted partner for global pharmaceutical companies in co-creating and empowering innovation in next-generation peptide therapies.